Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acet...(other study in pediatric patients in the...),Health

Acetavance Pivotal Phase III Enrollment Status

Efficacy Trials

Treatment of pain following total

knee & hip replacement Completed

Treatment of pain following abdominal

gynecologic surgery Completed

Treatment of fever in adults (vs.

placebo) Completed

Treatment of fever in adults (onset

of action) Completed

Treatment of pain following abdominal

laparoscopic surgery Initiated in Fourth Quarter 2007

Other Acetavance Trials Enrollment Status

Adult pharmacokinetics Completed

Adult safety Initiation in First Quarter 2008

Pediatric pharmacokinetics Actively enrolling

Pediatric safety Initiation in First Quarter 2008

The company also indicated that it remains on track to complete patient enrollment in its pivotal Phase III clinical trial of Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections in the second quarter of 2008.

Conference Call and Webcast at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time

Cadence management will host a conference call on January 11, 2008, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss today's announcement. Interested investors may participate in the conference call by dialing 888-233-7853 (domestic) or 913-981-5596 (international). To access the webcast, please log on to the company's website at http://www.cadencepharm.com and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's webs
'/>"/>